FR2751343B1 - Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament - Google Patents

Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Info

Publication number
FR2751343B1
FR2751343B1 FR9608851A FR9608851A FR2751343B1 FR 2751343 B1 FR2751343 B1 FR 2751343B1 FR 9608851 A FR9608851 A FR 9608851A FR 9608851 A FR9608851 A FR 9608851A FR 2751343 B1 FR2751343 B1 FR 2751343B1
Authority
FR
France
Prior art keywords
medicament
aqueous
preservation
recombinant viruses
viral suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9608851A
Other languages
English (en)
French (fr)
Other versions
FR2751343A1 (fr
Inventor
Claude Sene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9608851A priority Critical patent/FR2751343B1/fr
Application filed by Transgene SA filed Critical Transgene SA
Priority to JP50569198A priority patent/JP3681401B2/ja
Priority to PCT/FR1997/001308 priority patent/WO1998002522A1/fr
Priority to DE69718612T priority patent/DE69718612T2/de
Priority to AU36986/97A priority patent/AU711409B2/en
Priority to AT97933740T priority patent/ATE231549T1/de
Priority to EP97933740A priority patent/EP0853660B1/fr
Priority to DK97933740T priority patent/DK0853660T3/da
Priority to ES97933740T priority patent/ES2187798T3/es
Priority to US09/043,187 priority patent/US6451256B1/en
Priority to CA002232604A priority patent/CA2232604C/fr
Publication of FR2751343A1 publication Critical patent/FR2751343A1/fr
Application granted granted Critical
Publication of FR2751343B1 publication Critical patent/FR2751343B1/fr
Priority to US10/218,564 priority patent/US20030082206A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FR9608851A 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament Expired - Fee Related FR2751343B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR9608851A FR2751343B1 (fr) 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
ES97933740T ES2187798T3 (es) 1996-07-16 1997-07-15 Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento.
DE69718612T DE69718612T2 (de) 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
AU36986/97A AU711409B2 (en) 1996-07-16 1997-07-15 Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
AT97933740T ATE231549T1 (de) 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
EP97933740A EP0853660B1 (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
JP50569198A JP3681401B2 (ja) 1996-07-16 1997-07-15 感染性組換えウイルスの保存方法、水性ウイルス懸濁液、および薬剤としての使用
PCT/FR1997/001308 WO1998002522A1 (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US09/043,187 US6451256B1 (en) 1996-07-16 1997-07-15 Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicine
CA002232604A CA2232604C (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
DK97933740T DK0853660T3 (da) 1996-07-16 1997-07-15 Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
US10/218,564 US20030082206A1 (en) 1996-07-16 2002-08-15 Method of preserving infectious recombinant viruses, aqueous viral suspension, and use as medicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9608851A FR2751343B1 (fr) 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Publications (2)

Publication Number Publication Date
FR2751343A1 FR2751343A1 (fr) 1998-01-23
FR2751343B1 true FR2751343B1 (fr) 1998-12-18

Family

ID=9494078

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9608851A Expired - Fee Related FR2751343B1 (fr) 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Country Status (11)

Country Link
US (2) US6451256B1 (enExample)
EP (1) EP0853660B1 (enExample)
JP (1) JP3681401B2 (enExample)
AT (1) ATE231549T1 (enExample)
AU (1) AU711409B2 (enExample)
CA (1) CA2232604C (enExample)
DE (1) DE69718612T2 (enExample)
DK (1) DK0853660T3 (enExample)
ES (1) ES2187798T3 (enExample)
FR (1) FR2751343B1 (enExample)
WO (1) WO1998002522A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
CA2353417C (en) * 1998-12-03 2008-04-22 Genzyme Corporation Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
FR2791999B1 (fr) * 1999-04-09 2001-09-07 Aventis Pharma Sa Composition destinee a la conservation d'adenovirus recombinants infectieux
CN1347450A (zh) * 1999-04-09 2002-05-01 阿文蒂斯药物股份有限公司 用于保存感染性重组腺病毒的组合物
CA2799545A1 (en) 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1284287A4 (en) * 2000-05-10 2004-10-13 Mitsubishi Pharma Corp METHOD FOR PRODUCING A VIRUS VECTOR
JP4550421B2 (ja) 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
BR0306925A (pt) * 2002-01-18 2004-11-09 Schering Ag Formulações estabilizadas de adenovìrus
KR100507794B1 (ko) * 2003-02-11 2005-08-17 한미약품 주식회사 고농도 레트로 바이러스 현탁액 제조 방법
EP1692279A4 (en) * 2003-11-19 2006-12-27 Merck & Co Inc VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
EP2536829B1 (en) 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
CA2878800A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
CN110590916A (zh) 2013-04-25 2019-12-20 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
KR102313153B1 (ko) 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
RU2695462C2 (ru) 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
US9721484B2 (en) 2014-06-23 2017-08-01 Humanetics Innovative Solutions, Inc. Shoulder kit assembly for crash test dummy
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
US10008130B2 (en) 2014-09-17 2018-06-26 Humanetics Innovative Solutions, Inc. Omni-directional shoulder assembly for crash test dummy
EP3256156B1 (en) 2015-02-13 2025-02-12 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
KR20220041966A (ko) 2016-04-05 2022-04-01 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
WO2017194655A1 (en) 2016-05-12 2017-11-16 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US20190330655A1 (en) 2016-12-28 2019-10-31 Transgene Sa Oncolytic viruses and therapeutic molecules
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
US12263197B2 (en) 2018-10-30 2025-04-01 The University Of Tokyo Oncolytic virus for cancer therapy
JOP20210106A1 (ar) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
CN121360236A (zh) 2019-03-01 2026-01-20 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BR112022018615A2 (pt) 2020-03-19 2022-12-20 Trizell Ltd Sistema de armazenamento de vírus sensível à temperatura
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
EP4303233A4 (en) 2021-02-01 2025-05-07 St Phi Therapeutics Co., Ltd. Targeted protein degradation system and use thereof
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
US20260015405A1 (en) 2022-07-01 2026-01-15 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
CN120380015A (zh) 2022-08-18 2025-07-25 特兰斯吉恩公司 嵌合痘病毒
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
CA2158935A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
FR2711523B1 (fr) * 1993-10-26 1996-02-16 Transgene Sa Procédé de préparation d'un aérosol viral.
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations

Also Published As

Publication number Publication date
EP0853660A1 (fr) 1998-07-22
US20030082206A1 (en) 2003-05-01
CA2232604A1 (fr) 1998-01-22
EP0853660B1 (fr) 2003-01-22
WO1998002522A1 (fr) 1998-01-22
DE69718612T2 (de) 2003-11-06
ATE231549T1 (de) 2003-02-15
CA2232604C (fr) 2005-06-28
US6451256B1 (en) 2002-09-17
JP3681401B2 (ja) 2005-08-10
DK0853660T3 (da) 2003-05-05
AU3698697A (en) 1998-02-09
DE69718612D1 (de) 2003-02-27
AU711409B2 (en) 1999-10-14
FR2751343A1 (fr) 1998-01-23
JP2000500026A (ja) 2000-01-11
ES2187798T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
FR2751343B1 (fr) Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
DK1261360T3 (da) Casein-afledte peptider og anvendelser deraf i behandling
SG17493G (en) Ozone decontamination of blood and blood products
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
ATE162078T1 (de) Morphogeninduzierte regenerierung der leber
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
DE69028144D1 (de) Verfahren zum Lagern von Erythrozyten
FI961536A0 (fi) Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste
WO2005052116A3 (en) Preservative-containing virus formulations
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
LV10195B (en) Composition for stabilizing blood plasma during pasteurization and pasteurized plasma solution for therapeutic use
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
FR2781158B1 (fr) Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
IS5956A (is) Notkun bisfosónsýra til varnar og meðhöndlunar sýkingaferla
GB9716611D0 (en) Virus preparations and methods
ATE103185T1 (de) Stabilisierung von biologischen und pharmazeutischen produkten waehrend der inaktivierung von viralen und bakteriellen keimen.
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
DE50008992D1 (de) Verfahren zur Inaktivierung von Viren
Docherty et al. Inactivation of herpes simplex virus types 1 and 2 by synthetic histidine peptides
Shigehisa et al. Inactivation of HIV in blood plasma by high hydrostatic pressure
ATE497784T1 (de) Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
RU98117264A (ru) Способ инактивации вируса иммунодефицита человека и других вирусов в плазме крови человека с сохранением функциональной активности белков плазмы крови

Legal Events

Date Code Title Description
ST Notification of lapse